“Modelling and functional analysis of clonal Evolution in Leishmania – possible role of non-coding RNAs and RNA modification”
Recipient: Gerald Spaeth, coordinator Agency: Campus France, MEAE, Type: Bi-national program France/Israel, 04/2018 – 03/2020 Leishmaniasis is among the five most serious parasitic diseases worldwide. The cutaneous form of the disease is prevalent in […]
ANR Patho-Methylome – The role of lysine methylation in host-pathogen interactions
The interaction between two eukaryotic genomes provides a fascinating example of co-evolution of host-parasite interactions. Two genomes, two epigenomes, two cellular systems living together. Our proposal focuses on the fascinating features of the interaction […]
International Mixed Unit ‘Inflammation and Leishmania infection’ (IMU-InflaLeish): Exploiting host-pathogen interaction for the discovery of novel anti-microbial drug targets and drug candidates.
Recipient: Gerald Spaeth, PI Agency: Pasteur Institute, Type: Collaborative grant, 01/2016 – 12/2019 Based on ongoing collaborative actions we propose the creation of an IMU between three teams at IP Paris (G. Spaeth), IP […]
PTR 539 – A multilevel systems approach to elucidate the host-Leishmania interactome and to identify host targets for anti-leishmanial drug discovery
Our PTR project investigates at the complex interface between the intracellular pathogen Leishmania and its macrophage host cell. We will apply systems-wide analyses to elucidate the molecular mechanisms underlying the reciprocal metabolic relationship between […]
PTR 496 – Investigating the reciprocal relationship between macrophage inflammasome activity and intracellular Leishmania infection
Our proposal aims to decipher novel subversion strategies used by Leishmania (i) to withstand, circumvent or inhibit anti-microbial activities of host macrophages and (ii) to interfere with the induction of Leishmania-specific immune responses. We […]
FP7 Anti-Parasitic Drug Discovery in Epigenetics (A-ParaDDisE)
We will employ a target-based strategy for the development of novel drug leads against epigenetic targets in schistosomiasis, leishmaniasis, Chagas disease and malariafocusing on key histone modifying enzymes (HME), in particular those involved in […]
ANR TransLeish – Discovery of druggable protein kinases in the protozoan parasite Leishmania donovani using hit compounds identified by phenotypic screening
The protozoan parasite Leishmania donovani causes fatal visceral leishmaniasis, one of the most neglected tropical diseases. In the absence of economic incentive, serious Research and Development (R&D) investments into anti-leishmanial drug development lack from […]
FP7 Targeting the Leishmania kinome for the development of novel anti-parasitic strategies (LeishDrug)
Visceral leishmaniasis is caused by the protozoan parasites Leishmania donovani and Leishmania infantum and is a potentially fatal disease in endemic areas around the world. During the infectious cycle, Leishmania alternate between the insect […]
2020Leishmania amazonensis Subverts the Transcription Factor Landscape in Dendritic Cells to Avoid Inflammasome Activation and Stall Maturation, Front Immunol . 2020 Jun 9;11:1098.
2020Dynamic imaging reveals surface exposure of virulent Leishmania amastigotes during pyroptosis of infected macrophages., J. Cell. Sci. 2020 May; (): .
2020Infectivity and Drug Susceptibility Profiling of Different Leishmania-Host Cell Combinations., Pathogens 2020 May; 9(5): .
2020SILAC-based quantitative proteomics reveals pleiotropic, phenotypic modulation in primary murine macrophages infected with the protozoan pathogen Leishmania donovani., J Proteomics 2020 Feb; 213(): 103617.
2020Targeting Macrophage Histone H3 Modification as a Leishmania Strategy to Dampen the NF-κB/NLRP3-Mediated Inflammatory Response., Cell Rep 2020 Feb; 30(6): 1870-1882.e4.
2019Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening, Sci Rep 2019 Jan;9(1):438.
2017The enemy within: Targeting host-parasite interaction for antileishmanial drug discovery, PLoS Negl Trop Dis 2017 Jun;11(6):e0005480.
2016Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth, Int J Parasitol Drugs Drug Resist 2017 04;7(1):42-50.
2016Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor, Eur J Med Chem 2017 Jan;125:696-709.
2016From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity, Antimicrob. Agents Chemother. 2016 05;60(5):2822-33.
+View full list of publications